Oprozomib
id:
oprozomib-264-16915385
title:
Oprozomib
text:
Oprozomib is an orally active second-generation proteasome inhibitor developed by Proteolix, which was acquired by Onyx Pharmaceuticals, an Amgen subsidiary, in 2009. It selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (PSMB5) and immunoproteasome (LMP7). It is being investigated for the treatment of hematologic malignancies, specifically, multiple myeloma, with Phase 1b studies ongoing. Being an epoxyketone derivative, oprozomib is structurally related to carf
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Oprozomib
date created:
date modified:
2023-02-08T21:30:34Z
main entity:
{"identifier":"Q25104721","url":"https://www.wikidata.org/entity/Q25104721"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/c/cf/Oprozomib.svg","width":512,"height":263}
fields total:
13
integrity:
15